相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Adi Diab et al.
CLINICAL CANCER RESEARCH (2022)
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory
Yujiro Kidani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Simon Eschweiler et al.
NATURE (2022)
CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer
Jian Hang Lam et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
McLane J. Watson et al.
NATURE (2021)
Pan-cancer single cell landscape of tumor-infiltrating T cells
Liangtao Zheng et al.
SCIENCE (2021)
Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer
Christopher A. Chuckran et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation
Alexandra Laine et al.
NATURE COMMUNICATIONS (2021)
Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
Helena Van Damme et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models
Joseph R. Campbell et al.
CANCER RESEARCH (2021)
CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver
Jan P. Nicolay et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function
Sarah K. Whiteside et al.
IMMUNOLOGY (2021)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Kai Tang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma
Zhouhong Ge et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2021)
CD39 Regulation and Functions in T Cells
Eleonora Timperi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4+ T cells in the draining lymph nodes of breast cancer
Atri Ghods et al.
MOLECULAR IMMUNOLOGY (2021)
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
Sarina A. Piha-Paul et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
Sho Isoyama et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells
Kazuki Satoh et al.
INTERNATIONAL IMMUNOLOGY (2021)
Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression
Jenny Stenstrom et al.
BREAST CANCER RESEARCH (2021)
A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells
Keunok Jung et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
Atsushi Tanaka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Kimberley M. Heinhuis et al.
JAMA ONCOLOGY (2020)
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Anthony R. Cillo et al.
IMMUNITY (2020)
Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes
Reiko Fukui et al.
ANTICANCER RESEARCH (2020)
Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab
Ryota Tamura et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling
Junbin Qian et al.
CELL RESEARCH (2020)
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Ani S. Balmanoukian et al.
CLINICAL CANCER RESEARCH (2020)
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models
Amanda Hanson et al.
PLOS ONE (2020)
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
Gregoire de Streel et al.
NATURE COMMUNICATIONS (2020)
Preclinical characterization of BMS-986218, a novel nonfucosylated anti-CTLA-4 antibody designed to enhance antitumor activity
John Engelhardt et al.
CANCER RESEARCH (2020)
A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)
Julio C. Chavez et al.
BLOOD (2020)
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
Isabelle Solomon et al.
NATURE CANCER (2020)
Tumors establish resistance to immunotherapy by regulating T-reg recruitment via CCR4
Lisa A. Marshall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
Lisanne Heim et al.
BRITISH JOURNAL OF CANCER (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Deepali Sawant et al.
NATURE IMMUNOLOGY (2019)
Rational design of anti-GITR-based combination immunotherapy
Roberta Zappasodi et al.
NATURE MEDICINE (2019)
Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25-Foxp3+ T cells
Magdalena J. Polanczyk et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Toshihiko Doi et al.
CLINICAL CANCER RESEARCH (2019)
Mitochondrial complex III is essential for suppressive function of regulatory T cells
Samuel E. Weinberg et al.
NATURE (2019)
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody
Danbee Ha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer
Dai Liu et al.
ONCOIMMUNOLOGY (2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells
Jonathan Powell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer
Koji Takada et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
The less-is-more in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
Natasha A. Pereira et al.
MABS (2018)
Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis
Ross A. Soo et al.
Oncotarget (2018)
PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells
Chaido Stathopoulou et al.
IMMUNITY (2018)
Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients.
Yosuke Togashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Low-dose cyclophosphamide depletes circulating naive and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
Lisanne Noordam et al.
ONCOIMMUNOLOGY (2018)
CCL1 is a major regulatory T cell attracting factor in human breast cancer
Benjamin Kuehnemuth et al.
BMC CANCER (2018)
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
Begoña Martin-Castillo et al.
Oncotarget (2018)
CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer
Ning Pu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori
Hirotsugu Nagase et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
CCR8+FOXp3+ Treg cells as master drivers of immune regulation
Yiftah Barsheshet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8
Julie Stockis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
Mayuko Uehara et al.
NATURE COMMUNICATIONS (2017)
Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis
Lejia Sun et al.
ONCOTARGET (2017)
Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer A Randomized Clinical Trial
Martin Scurr et al.
JAMA ONCOLOGY (2017)
Attenuation of CD4+ CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug
Yuki Kunisada et al.
EBIOMEDICINE (2017)
Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells
Selvakumar Sukumar et al.
CANCER RESEARCH (2017)
Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
Nicolas A. Giraldo et al.
CLINICAL CANCER RESEARCH (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Takeru Asano et al.
BLOOD (2017)
Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
Shamim Ahmad et al.
CANCER RESEARCH (2017)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Jason D. Fontenot et al.
JOURNAL OF IMMUNOLOGY (2017)
Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy
Kieu-Suong Le et al.
CANCER RESEARCH (2016)
Treg stability: to be or not to be
Abigail E. Overacre et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Targeting regulatory T cells in tumors
Chang Liu et al.
FEBS JOURNAL (2016)
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses
Lindsay K. Ward-Kavanagh et al.
IMMUNITY (2016)
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
Marco De Simone et al.
IMMUNITY (2016)
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
George Plitas et al.
IMMUNITY (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
Role of NRP-1 in VEGF-VEGFR2-Independent Tumorigenesis
Chenxi Hu et al.
TARGETED ONCOLOGY (2016)
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis
Laura Negrotto et al.
JAMA NEUROLOGY (2016)
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
Alexander S. Baras et al.
ONCOIMMUNOLOGY (2016)
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
Daniel E. Lowther et al.
JCI INSIGHT (2016)
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
Madeleine Duvic et al.
BLOOD (2015)
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M. E. Gore et al.
BRITISH JOURNAL OF CANCER (2015)
Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients
Fan Yan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie et al.
CANCER RESEARCH (2015)
Integrin αvβ8-Mediated TGF-β Activation by Effector Regulatory T Cells Is Essential for Suppression of T-Cell-Mediated Inflammation
John J. Worthington et al.
IMMUNITY (2015)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Sil Kordes et al.
LANCET ONCOLOGY (2015)
Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability
Alexandria Huynh et al.
NATURE IMMUNOLOGY (2015)
Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Shingo Eikawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
Julia Cuende et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients
I. Wertel et al.
TUMOR BIOLOGY (2015)
T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine
Kristen L. Dennis et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer
Xiao-Mei Huang et al.
CANCER SCIENCE (2014)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1-or Melan-A-Specific T Cells
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2014)
Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
Nicole Joller et al.
IMMUNITY (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells
Shawn A. Mahmud et al.
NATURE IMMUNOLOGY (2014)
Prognostic significance of FOXP3+tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2014)
Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
N. R. West et al.
BRITISH JOURNAL OF CANCER (2013)
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+Tregs within the tumor microenvironment
Chindu Govindaraj et al.
CLINICAL IMMUNOLOGY (2013)
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
C. Andrew Stewart et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis
Greg M. Delgoffe et al.
NATURE (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
David A. Schaer et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells
Thomas Duhen et al.
BLOOD (2012)
Epidermis instructs skin homing receptor expression in human T cells
Michelle L. McCully et al.
BLOOD (2012)
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Yingzi Ge et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells
Julien Faget et al.
CANCER RESEARCH (2012)
CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
Nassima Redjimi et al.
CANCER RESEARCH (2012)
Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells
Curdin Conrad et al.
CANCER RESEARCH (2012)
The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
Ronald J. deLeeuw et al.
CLINICAL CANCER RESEARCH (2012)
Complexities of TGF-β Targeted Cancer Therapy
Erin C. Connolly et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Wiebke Hansen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2012)
Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth
Eva Schlecker et al.
JOURNAL OF IMMUNOLOGY (2012)
GARP regulates the bioavailability and activation of TGFβ
Rui Wang et al.
MOLECULAR BIOLOGY OF THE CELL (2012)
Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells
Hiroyuki Tao et al.
LUNG CANCER (2012)
The composition and signaling of the IL-35 receptor are unconventional
Lauren W. Collison et al.
NATURE IMMUNOLOGY (2012)
CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
Andrew J. Rech et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment
Christine Menetrier-Caux et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
FOXP3 and survival in urinary bladder cancer
Malin E. Winerdal et al.
BJU INTERNATIONAL (2011)
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
Duane A. Mitchell et al.
BLOOD (2011)
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer
Sylvain Ladoire et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer
Marie Tosolini et al.
CANCER RESEARCH (2011)
A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix
Walayat Shah et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2011)
The imbalance of Th17/Treg in patients with uterine cervical cancer
Yan Zhang et al.
CLINICA CHIMICA ACTA (2011)
Prognostic Immune Markers in Non-Small Cell Lung Cancer
Kei Suzuki et al.
CLINICAL CANCER RESEARCH (2011)
Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests
Jacek J. Sznurkowski et al.
GYNECOLOGIC ONCOLOGY (2011)
Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation
Ashutosh Chaudhry et al.
IMMUNITY (2011)
Resolving the identity myth: Key markers of functional CD4+FoxP3+ regulatory T cells
Xin Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
Ingrid M. E. Desar et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller et al.
JOURNAL OF IMMUNOLOGY (2011)
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling
Wei Tan et al.
NATURE (2011)
Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer
Hiroyuki Suzuki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells
Natalia Martin-Orozco et al.
CANCER RESEARCH (2010)
Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
Joannes F. M. Jacobs et al.
CLINICAL CANCER RESEARCH (2010)
Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood
Xin Chen et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck
Jan Boucek et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Regulatory T-cell stability and plasticity in mucosal and systemic immune systems
M. Murai et al.
MUCOSAL IMMUNOLOGY (2010)
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Kajsa Wing et al.
NATURE IMMUNOLOGY (2010)
IL-35-mediated induction of a potent regulatory T cell population
Lauren W. Collison et al.
NATURE IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor-infiltrating lymphocytes, particularly the balance between CD8+ T cells and CCR4+ regulatory T cells, affect the survival of patients with oral squamous cell carcinoma
Yoshiko Watanabe et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2010)
Correlation of CXCL12 Expression and FoxP3+ Cell Infiltration with Human Papillomavirus Infection and Clinicopathological Progression of Cervical Cancer
Fatimah Jaafar et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25
Jing Chen et al.
BLOOD (2009)
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
Ninke Leffers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer
R. A. de Jong et al.
GYNECOLOGIC ONCOLOGY (2009)
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
Makoto Miyara et al.
IMMUNITY (2009)
OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity
Naomi Kitamura et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer
Paul Salama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer
Marcus C. B. Tan et al.
JOURNAL OF IMMUNOLOGY (2009)
Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis
Masako Murai et al.
NATURE IMMUNOLOGY (2009)
GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells
Dat Q. Tran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma
T. Yoshioka et al.
BRITISH JOURNAL OF CANCER (2008)
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio:: Which variable determines survival of cervical cancer patients?
Ekaterina S. Jordanova et al.
CLINICAL CANCER RESEARCH (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma
A. Sasaki et al.
EJSO (2008)
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
Giuseppe Perrone et al.
EUROPEAN JOURNAL OF CANCER (2008)
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
Alexandar Tzankov et al.
HAEMATOLOGICA (2008)
Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition
Milka Sarris et al.
IMMUNITY (2008)
Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells:: Implications and impact on tumor-mediated immune suppression
Laura Strauss et al.
JOURNAL OF IMMUNOLOGY (2008)
Expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells:: Applicability to tumor-infiltrating T regulatory cells
Xin Chen et al.
JOURNAL OF IMMUNOLOGY (2008)
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
Masaki Anraku et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2008)
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
C. M. Lucas et al.
LEUKEMIA (2008)
How regulatory T cells work
Dario A. A. Vignali et al.
NATURE REVIEWS IMMUNOLOGY (2008)
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Lauren W. Collison et al.
NATURE (2007)
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
Richard W. Griffiths et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
Qiang Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients
Junliang Fu et al.
GASTROENTEROLOGY (2007)
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production
Sarah E. Allan et al.
INTERNATIONAL IMMUNOLOGY (2007)
Interleukin-7 receptor expression: intelligent design
Renata Mazzucchelli et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Transient expression of FOXP3 in human activated nonregulatory CD4(+) T cells
Jun Wang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients
Rebecca P. Petersen et al.
CANCER (2006)
In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer
Christoph Loddenkemper et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes
Dulce Soler et al.
JOURNAL OF IMMUNOLOGY (2006)
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions
Nobuyoshi Hiraoka et al.
CLINICAL CANCER RESEARCH (2006)
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Weihong Liu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells
Nabila Seddiki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice
KL Knutson et al.
JOURNAL OF IMMUNOLOGY (2006)
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development (vol 103, pg 6659, 2006)
MA Gavin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development
MA Gavin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
GC Cesana et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CD4(+)CD25(high) regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers
Koji Kono et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Effector memory T cells, early metastasis, and survival in colorectal cancer
F Pagès et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
D Wolf et al.
CLINICAL CANCER RESEARCH (2005)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
J Dannull et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
P Attia et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
LA Ormandy et al.
CANCER RESEARCH (2005)
Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells
HY Wang et al.
JOURNAL OF IMMUNOLOGY (2005)
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivoi
ML Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
A skin-selective homing mechanism for human immune surveillance T cells
P Schaerli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2003)
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
E Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3
CL Bennett et al.
NATURE GENETICS (2001)
分享论文
